vimarsana.com
Home
Live Updates
NDA for New Second-Line Indication of CAR T-Cell Therapy Pro
NDA for New Second-Line Indication of CAR T-Cell Therapy Pro
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
/PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for...
Related Keywords
China ,
Shanghai ,
Huang Hai ,
Jiangsu ,
Monica Li ,
Kite Pharma Inc ,
National Medical Products Administration ,
Fosun Kite Biotechnology Co Ltd ,
Axicabtagene Ciloleucel Cell Therapy Center ,
Fosun Kite ,
Showcase New Options ,
Cell Therapy ,
Drug Evaluation ,
Kite Pharma ,